biological therapies barbiturates

38
MARIA FE SALVADOR NAVARRETE MD BIOLOGICAL THERAPIES

Upload: nilesh-kucha

Post on 12-Nov-2014

368 views

Category:

Documents


5 download

DESCRIPTION

 

TRANSCRIPT

Page 1: Biological therapies barbiturates

MARIA FE SALVADOR NAVARRETE MD

BIOLOGICAL THERAPIES

Page 2: Biological therapies barbiturates

Barbiturates and Similarly Acting Drugs

used as sedative-hypnotic agents in 20th century\ high abuse and addiction potential, a narrow therapeutic range with low therapeutic index, and unfavorable side effects. The use of barbiturates and similar compounds such

as meprobamate (Miltown) has been practically eliminated by the benzodiazepines,

buspirone (BuSpar), and hypnotics such as zolpidem (Ambien) and zaleplon (Sonata), which have a lower abuse potential and a higher therapeutic index than the barbiturates.

the barbiturates and similarly acting drugs still have a role in the treatment of certain mental disorders.

Page 3: Biological therapies barbiturates

Pharmacologic Actions

well absorbed after oral administration. The binding of barbiturates to plasma proteins is high,

but lipid solubility varies. metabolized by the liver and excreted by the kidneys. The half-lives of specific barbiturates range from 1 to

120 hours (Table 36.8-1). Barbiturates may also induce hepatic enzymes

(cytochrome P450), thereby reducing the levels of both the barbiturate and any other concurrently administered drugs metabolized by the liver.

The mechanism of action of barbiturates involves the γ-aminobutyric acid (GABA) receptor–benzodiazepine receptor–chloride ion channel complex.

Page 4: Biological therapies barbiturates

Therapeutic Indications:Electroconvulsive Therapy Methohexital (Brevital) is commonly used as an

anesthetic agent for electroconvulsive therapy (ECT).

It has lower cardiac risks Used intravenously, methohexital produces

rapid unconsciousness and, because of rapid redistribution, it has a brief duration of action (5 to 7 minutes)

Typical dosing for ECT is 0.7 to 1.2 mg/kg. Methohexital can also be used to abort prolonged seizures in ECT or to limit postictal agitation.

Page 5: Biological therapies barbiturates

Seizures

Phenobarbital (Solfoton, Luminal), the most commonly used barbiturate for treatment of seizures, has indications for the treatment of generalized tonic-clonic and simple partial seizures.

Parenteral barbiturates are used in the emergency management of seizures independent of cause. Intravenous (IV) phenobarbital should be administered slowly, 10 to 20 mg/kg for status epilepticus.

Page 6: Biological therapies barbiturates

Narcoanalysis

Amobarbital (Amytal) has been used historically as a diagnostic aid in a number of clinical conditions,

including conversion reactions, catatonia, hysterical stupor, and unexplained muteness, and to differentiate stupor of depression, schizophrenia, and structural brain

lesions.

Page 7: Biological therapies barbiturates

SLEEP

The barbiturates reduce sleep latency and the number of awakenings during sleep, although tolerance to these effects generally develops within 2 weeks.

Discontinuation of barbiturates often leads to rebound increases on electroencephalogram (EEG) measures of sleep and a worsening of the insomnia.

Page 8: Biological therapies barbiturates

Withdrawal from Sedative-Hypnotics used to determine the extent of tolerance to barbiturates or

other hypnotics to guide detoxification. a test dose of pentobarbital (200 mg) is given orally. An hour later the patient is examined. Tolerance and dose requirements are determined by the degree

to which the patient is affected If the patient is not sedated, another 100 mg of pentobarbital

can be administered every 2 hours, up to three times (maximum, 500 mg over 6 hours).

The amount needed for mild intoxication corresponds to the approximate daily dose of barbiturate used.

Phenobarbital (30 mg) may then be substituted for each 100 mg of pentobarbital.

daily dose requirement can be administered in divided doses and gradually tapered by 10 percent a day, with adjustments made according to withdrawal signs (Table 36.8-2).

Page 9: Biological therapies barbiturates

Precautions and Adverse Reactions paradoxical dysphoria, hyperactivity, and cognitive disorganization. Rare adverse effects associated with

barbiturate use include the development of Stevens-Johnson syndrome,

megaloblastic anemia, and neutropenia.

Page 10: Biological therapies barbiturates

A major difference between the barbiturates and the benzodiazepines is the low therapeutic index of the barbiturates. An overdose of barbiturates can easily prove fatal

Page 11: Biological therapies barbiturates

Barbiturate intoxication is manifested by confusion, drowsiness, irritability, hyporeflexia or areflexia, ataxia, and nystagmus.

Page 12: Biological therapies barbiturates

Because of some evidence of teratogenicity, barbiturates should not be used by pregnant women or women who are breast-feeding.

Barbiturates should be used with caution by patients with a history of substance abuse, depression, diabetes, hepatic impairment, renal disease, severe anemia, pain, hyperthyroidism, or hypoadrenalism

Page 13: Biological therapies barbiturates

Drug Interactions

The primary area for concern about drug interactions is the potentially additive effects of respiratory depression.

Barbiturates should be used with great caution with other prescribed central nervous system (CNS) drugs (including antipsychotic and antidepressant drugs) and nonprescribed CNS agents (e.g., alcohol)

Page 14: Biological therapies barbiturates

Paraldehyde

Paraldehyde is a cyclic ether, first used in 1882 as a hypnotic. It has also been used to treat epilepsy, alcohol withdrawal symptoms, and delirium tremens. Because of its low therapeutic index, it has been supplanted by the benzodiazepines and other anticonvulsants

Page 15: Biological therapies barbiturates

Precautions and Adverse Reactions Paraldehyde frequently causes foul

breath because of expired unmetabolized drug. It can inflame pulmonary capillaries and cause coughing. It can also cause local thrombophlebitis with IV use. Patients may experience nausea and vomiting with oral use. Overdose leads to metabolic acidosis and decreased renal output. There is risk of abuse among drug addicts.

Page 16: Biological therapies barbiturates

Drug Interactions

Disulfiram (Antabuse) inhibits acetaldehyde dehydrogenase and reduces metabolism of paraldehyde, leading to possible toxic concentration of paraldehyde. Paraldehyde has addictive sedating effects in combination with other CNS depressants such as alcohol or benzodiazepines.

Page 17: Biological therapies barbiturates

Meprobamate

Meprobamate, a carbamate, was introduced shortly before the benzodiazepines, specifically to treat anxiety. It is also used for muscle relaxant effects.

Page 18: Biological therapies barbiturates

Chloral Hydrate Chloral hydrate is a hypnotic agent

rarely used in psychiatry because numerous safer options, such as benzodiazepines, are available.

Page 19: Biological therapies barbiturates

Benzodiazepines and Drugs Acting on Benzodiazepine Receptors

modulate γ-aminobutyric acid (GABA) activity. Nonbenzodiazepine agonists, such zolpidem

(Ambien), zaleplon (Sonata), and eszopiclone (Lunesta)—the so-called “Z drugsâ€â€” �interactions with GABA-receptor complexes at binding domains located close to or coupled to benzodiazepine receptors.

Flumazenil (Romazicon), a benzodiazepine receptor antagonist used to reverse benzodiazepine-induced sedation and in emergency care of benzodiazepine overdosage

Page 20: Biological therapies barbiturates

With the exception of clorazepate (Tranxene), all the benzodiazepines are completely absorbed unchanged from the gastrointestinal (GI) tract.

The absorption, the attainment of peak concentrations, and the onset of action are quickest for diazepam (Valium), lorazepam (Ativan), alprazolam (Xanax), triazolam (Halcion), and estazolam (ProSom).

Page 21: Biological therapies barbiturates

rapid anxiolytic sedative effect, they are most commonly used for immediate treatment of insomnia, acute anxiety, and agitation or anxiety associated with any psychiatric disorder.

used as anesthetics, anticonvulsants, and muscle relaxants.

Because of the risk of psychological and physical dependence, long-term use of benzodiazepines should be in conjunction with psychotherapy and in cases where alternative agents have been tried and proved ineffective or poorly tolerated.

Page 22: Biological therapies barbiturates

Diazepam, chlordiazepoxide, clonazepam (Klonopin), clorazepate, flurazepam (Dalmane), prazepam (Centrax), quazepam (Doral), and halazepam (Paxipam) have plasma half-lives of 30 to more than 100 hours and, therefore, are the longest-acting benzodiazepines

Page 23: Biological therapies barbiturates

Gaboxatal This is a new hypnotic agent which

works on the α-4 GABA receptor subtype rather than on the α-1 GABA subtype which the other benzodiazepines effect. α-4 GABA is expressed at high levels in the thalmus.

Page 24: Biological therapies barbiturates

Therapeutic Indications

Insomnia Because insomnia can be a symptom

of a physical or psychiatric disorder, hypnotics should not be used for more than 7 to 10 consecutive days without a thorough investigation of the cause of the insomnia.

Page 25: Biological therapies barbiturates

Anxiety Disorders Generalized Anxiety Disorder Benzodiazepines are highly effective for

the relief of anxiety associated with generalized anxiety disorder.

Because generalized anxiety disorder is a chronic disorder with a high rate of recurrence, some persons with generalized anxiety disorder may warrant long-term maintenance treatment with benzodiazepines.

Page 26: Biological therapies barbiturates

Panic Disorder Alprazolam and clonazepam, both high-

potency benzodiazepines, are commonly used medications for panic disorder, with or without agoraphobia.

Although the selective serotonin reuptake inhibitors (SSRIs) are also indicated for treatment of panic disorder, benzodiazepines have the advantage of working quickly and of not causing significant sexual dysfunction and weight gain.

Page 27: Biological therapies barbiturates

Social Phobia Clonazepam has been shown to be

an effective treatment for social phobia. In addition, several other benzodiazepines (e.g., diazepam) have been used as adjunctive medications for treatment of social phobia.

Page 28: Biological therapies barbiturates

Other Anxiety Disorders Benzodiazepines are used

adjunctively for treatment of adjustment disorder with anxiety, pathological anxiety associated with life events (e.g., after an accident), OCD, and posttraumatic stress disorder.

Page 29: Biological therapies barbiturates

Mixed Anxiety–Depressive Disorder

Alprazolam is indicated for the treatment of anxiety associated with depression.

Page 30: Biological therapies barbiturates

Bipolar I Disorder Clonazepam, lorazepam, and

alprazolam are effective in the management of acute manic episodes and as an adjuvant to maintenance therapy in lieu of antipsychotics. As an adjuvant to lithium (Eskalith) or lamotrigine (Lamictal), clonazepam may result in an increased time between cycles and fewer depressive episodes.

Page 31: Biological therapies barbiturates

Akathisia The first-line drug for akathisia is

most commonly a β-adrenergic receptor antagonist. Benzodiazepines are also effective in treating some patients with akathisia

Page 32: Biological therapies barbiturates

Parkinson's Disease A few persons with idiopathic

Parkinson's disease will respond to long-term use of zolpidem with reduced bradykinesia and rigidity. Zolpidem dosages of 10 mg four times daily may be tolerated without sedation for several years.

Page 33: Biological therapies barbiturates

Precautions and Adverse Reactions The most common adverse effect of

benzodiazepines is drowsiness, which occurs in about 10 percent of all persons.

Page 34: Biological therapies barbiturates

Signs and Symptoms of Benzodiazepine Withdrawal Anxiety Tremor Irritability Depersonalization Insomnia Hyperesthesia Hyperacusis Myoclonus Nausea Delirium Difficulty concentrating Seizures

Page 35: Biological therapies barbiturates

Drug Interactions

The most common and potentially serious benzodiazepine receptor agonist interaction results in excessive sedation and respiratory depression occurring when benzodiazepines, zolpidem, or zaleplon are administered concomitantly with other CNS depressants, such as alcohol, barbiturates, tricyclic and tetracyclic drugs, dopamine receptor antagonists (DRAs), opioids, and antihistamines.

Page 36: Biological therapies barbiturates

RAMELTEON

Ramelteon (Rozerem), a new treatment for insomnia, was approved by the US Food and Drug Administration (FDA) in 2005.

Page 37: Biological therapies barbiturates

Pharmacologic Actions

Unlike the other hypnotic agents discussed in this section, ramelteon does not act on the benzodiazepine or GABA system.

It specifically targets the melatonin MT1 and MT2 receptors in the brain's suprachiasmatic nucleus (SCN). The SCN regulates 24-hour, or circadian, rhythms including the sleep–wake cycle.

Page 38: Biological therapies barbiturates

THANK YOU

POWER!!!!!!!!!!!!!!!!